Ziftomenib
Small molecule
Also known as KO-562
Evidence outlook
Approved: Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also in development:Acute Lymphoblastic Leukemia · Phase 1/2
Company guidance: topline data expected in 2028 (Kura Oncology, Inc., 10 Nov 2026). “o Initial topline results from the frontline KOMET-017 registrational program are anticipated in 2028, representing a key milestone in evaluating the potential to expand ziftomenib into newly diagnosed AML.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07007312 NCT07007312 · Acute Myeloid Leukemia (AML) Registry: NCT07007312 | 3 | Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS) (Defined as the time from randomization to date of death from any cause, assessed up to 36 months after last patient inclusion); Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) (Assessed up to 36 months after last patient inclusion); Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS) (Defined as the time from randomization to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months after last patient inclusion); Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients (Assessed up to 36 months after last patient inclusion) 2031-11 | In progress: results expected 1 Nov 2031 | not yet graded | link ↗ |
View 1 more trial
NCT04067336 NCT04067336 · Acute Myeloid Leukemia All phase 2 participants received ziftomenib in an open-label single group, with no blinding and no comparison arm; the only randomization was between two doses in an earlier dose-finding phase. The remission rate was tested against a fixed benchmark rate rather than against patients given another treatment, so the study cannot show how ziftomenib compares with alternatives. Registry: NCT04067336 | 1/2 | Phase 1a: Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) (Dose Limiting Toxicities (DLTs) will be evaluated during the first 28 days (1 cycle)); Phase 1b: Number of patients who experience Adverse Events (AEs) and Serious Adverse Events (SAEs) (During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.); Phase 1b: Minimum biologically effective dose (For at least 12 months following end of treatment); Phase 1a, 1b, and 2: Evidence of anti-leukemia activity (For at least 12 months following end of treatment); Sub-study 1: Time to observed maximum plasma concentration (Tmax) of ziftomenib and midazolam (Cycle 1 on Days 1 and 15 at predose and postdose); Sub-study 1: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and midazolam (Cycle 1 on Days 1 and 15 at predose and postdose); Sub-study 1: Maximum observed plasma concentration (Cmax) of ziftomenib and midazolam (Cycle 1 on Days 1 and 15 at predose and postdose); Sub-study 2: Time to observed maximum plasma concentration (Tmax) of ziftomenib and itraconazole (Cycle 1 on Days 1, 15, and 22 at predose and postdose); Sub-study 2: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and itraconazole (Cycle 1 on Days 1, 15, and 22 at predose and postdose); Sub-study 2: Maximum observed plasma concentration (Cmax) of ziftomenib and itraconazole (Cycle 1 on Days 1, 15, and 22 at predose and postdose); Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D) (During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first); Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D) (For at least 12 months following end of treatment); Sub-study 3: Change in Eastern Cooperative Oncology Group (ECOG) status (Timeframe: from Baseline to End of Treatment); Sub-study 3: Time to observed maximum plasma concentration (Tmax) of ziftomenib (Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards); Sub-study 3: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib (Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards); Sub-study 3: Maximum observed plasma concentration (Cmax) of ziftomenib (Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards.); Sub-study 4: Complete remission (CR) and complete remission with partial hematologic recovery (CRh) (For at least 12 months following end of treatment) 2028-10-16 | In progress: results expected 16 Oct 2028 | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Menin drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Acute Lymphoblastic Leukemia: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ziftomenib: this drug | Phase 1/2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Approved | Multispecific antibody | CD19 x CD3 | Weak signal | NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6) | |
| Methotrexate | Approved | Small molecule | Dihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Ponatinib (ICLUSIG) | Approved | Small molecule | BCR-ABL (including T315I) | Partial signal | Featured results are non-efficacy only in this race | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Icovamenib | Phase 2(overall) | Small molecule | Menin | Partial signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ziftomenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (6)
January 2028 (1)
What to watch
September 2028 (1)
What to watch
October 2028 (1)
What to watch
December 2028 (3)
What to watch
What to watch
What to watch
2029 (2)
February 2029 (1)
What to watch
June 2029 (1)
What to watch
2030 (1)
April 2030 (1)
What to watch
2031 (1)
November 2031 (1)
What to watch
2033 (1)
March 2033 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent